Online first
Case report
Published online: 2025-01-20

open access

Page views 73
Article views/downloads 33
Get Citation

Connect on Social Media

Connect on Social Media

Paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of the lung: A case report and literature review

Dominika Czarnecka1, Ewa Pasierbska1

Abstract

Bullous pemphigoid (BP) is a common autoimmune subepidermal blistering disorder that predominantly affects the elderly and is characterized by autoantibodies against BP230 and BP180. While its aetiology remains uncertain, BP has been associated with medications, infections, and neoplasms, including paraneoplastic manifestations. This report highlights a rare case of paraneoplastic BP in a 72-year-old male with squamous cell carcinoma (SCC) of the lung, emphasizing the importance of recognizing BP as a potential cutaneous marker of internal malignancies. The patient presented with itchy, tense blisters on an erythematous base, erosions, and crusts, confirmed as BP through immunopathological testing. Imaging revealed a lung tumour, later diagnosed as SCC with mediastinal and right hilar lymphadenopathy. Despite topical steroid treatment for BP and subsequent oncologic consultations, the patient’s condition progressed. The skin lesions exacerbated alongside the malignancy, and he was eventually referred to the hospital again. This case underscores the potential paraneoplastic nature of BP and its association with lung SCC, which remains poorly understood. Notably, recent reports indicate that BP may resolve following successful cancer treatment, further suggesting a pathogenic link. However, therapeutic challenges persist, particularly in cases of advanced malignancy or treatment resistance. Innovative therapies, such as omalizumab and Janus kinase inhibitors, have shown promise in managing refractory BP, including cases induced by immune checkpoint inhibitors. Clinicians should consider comprehensive cancer screening in patients with refractory BP, as early identification of associated malignancies may improve outcomes. Further studies are warranted to elucidate the underlying mechanisms connecting BP and neoplasms, refine diagnostic approaches, and expand treatment options. This case contributes to the growing evidence of BP as a paraneoplastic phenomenon, particularly in the context of SCC.

Article available in PDF format

View PDF Download PDF file

References

  1. Woźniak K, Dmochowski M, Placek W, et al. Pemphigoid – diagnosis and treatment. Polish Dermatological Society Consensus. Dermatol Rev. 2016; 103(1): 19–34.
  2. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: A review of the literature. J Eur Acad Dermatol Venereol. 2014; 28(9): 1133–1140.
  3. Ogawa H, Sakuma M, Morioka S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995; 9(2): 136–141.
  4. Białynicki-Birula R, Gajdzis P. Bullous pemphigoid induced by vaccinations. Dermatol Klin. 2008; 10(1): 37–40.
  5. Barnadas MA, Gilaberte M, Pujol R, et al. Bullous pemphigoid in a patient with psoriasis during the course of PUVA therapy: study by ELISA test. Int J Dermatol. 2006; 45(9): 1089–1092.
  6. Preesman AH, Toonstra J, Van der Putte SC, et al. UV-B-induced bullous pemphigoid restricted to mycosis fungoides plaques. Clin Exp Dermatol. 1990; 15(5): 363–366.
  7. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol. 2005; 141(6): 691–698.
  8. Reich A, Szepietowski JC, Bialynicki-Birula R, et al. Bullous pemphigoid in a patient with giant squamous cell carcinoma of the groin. Acta Dermatovenerol APA. 2004; 13: 58–62.
  9. Benhiba H, Hassam B. Association of bullous pemphigoïd and squamous cell carcinoma of the lip: a simple coïncidence? Pan Afr Med J. 2015; 20: 396.
  10. Shrestha P, George MK, Baidya S, et al. Bullous pemphigoid associated with squamous cell lung carcinoma showing remarkable response to carboplatin-based chemotherapy: A case report. J Med Case Rep. 2022; 16(1): 184.
  11. Youh J, Mizukami T, Nagata Y, et al. Resolution of bullous pemphigoid following lung cancer resection: A case of paraneoplastic pemphigoid. Cureus. 2024; 16(11): e73485.
  12. Guan S, Zhang L, Zhang J, et al. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy. Front Immunol. 2022; 13: 1068978.
  13. Chen J, Xu D, He Z, et al. Successful treatment of immune checkpoint inhibitor-induced bullous pemphigoid with omalizumab: A case report and review of the literature. Clin Cosmet Investig Dermatol. 2024; 17: 2865–2874.
  14. Gresham LM, Kirchhof MG. A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report. SAGE Open Med Case Rep. 2023; 11: 2050313X231160926.